Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 | Q99500 | 9/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.33 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.33 |
| ▸ | KIT | P10721 | 2/20 | 0.33 |
| ▸ | IDH1 | O75874 | 3/20 | 0.32 |
| ▸ | VCP | P55072 | 1/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.31 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31145890 | 1.00 | S1PR3 (0.36) | S1PR3PDPK1LRRK2S1PR1S1PR2 | |
| SCHEMBL31146204 | 0.84 | S1PR3 (0.35) | S1PR3PDPK1LRRK2S1PR1S1PR2 | |
| SCHEMBL31146015 | 0.83 | S1PR3 (0.36) | S1PR3PDPK1LRRK2S1PR1KIT | |
| SCHEMBL31359019 | 0.76 | PDPK1 (0.36) | S1PR3PDPK1KIT | |
| SCHEMBL31161003 | 0.76 | PDPK1 (0.36) | S1PR3PDPK1KIT | |
| SCHEMBL31146177 | 0.74 | PDPK1 (0.34) | PDPK1LRRK2IDH1 | |
| SCHEMBL31145795 | 0.74 | PDPK1 (0.34) | PDPK1LRRK2IDH1 | |
| SCHEMBL31145930 | 0.74 | PDPK1 (0.34) | PDPK1LRRK2IDH1 | |
| SCHEMBL31146049 | 0.71 | PTGS2 (0.36) | — | |
| SCHEMBL31145935 | 0.71 | PTGS2 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688748-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260008774-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-12448369-B2 | Quinolinone amide compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20250026740-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2025-01-23 | — | — | US | disclosed |
| WO-2024206339-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2024-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12448369-B2 | Quinolinone amide compounds and uses thereof | TNNI3, TNNT2, COQ8A | S1PR3 4572/4885PDPK1 1251/4885LRRK2 2957/4885 |
| US-20250026740-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, COQ8A | S1PR3 4572/4885PDPK1 1251/4885LRRK2 2957/4885 |
| US-20260008774-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | TNNT2, TNNI3, TNNC1 | S1PR3 1054/4885PDPK1 3943/4885LRRK2 3161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.